AstraZeneca PLC (AZN) Financials

AZN

FY2025 annual

Revenue $58.7B +8.6% YoY

Net Income $10.2B +45.3% YoY

Free Cash Flow $11.8B +18.4% YoY

Operating Cash Flow $14.6B +22.9% YoY

Market Cap $244.6B as of Oct 1, 2026

Price / Sales 4.2x on $58.7B revenue, FY2025

Price / Earnings 23.9x on $10.2B net income, FY2025

Price / Book 5.0x on $48.7B equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 1, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Feb 24, 2026 Currency USD FYE December

Newest figures come from the 10-K for FY2025, filed Feb 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AZN SEC filings page.

AstraZeneca PLC (AZN) reported $58.7B in revenue for fiscal year 2025, up 8.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AZN FY2025 2026-09-05

AstraZeneca’s 2025 acceleration shows earnings scaling faster than sales while cash generation stays ahead of accounting profit despite heavier reinvestment.

From FY2024 to FY2025, revenue rose 8.6% while net margin widened materially, so earnings acceleration was not merely volume-driven. Operating cash flow exceeded net income in both years even as capital spending climbed, indicating earnings were accompanied by cash rather than relying on accruals.

Short-term liquidity remains structurally tight: the current ratio stayed below 1.0x in FY2025 after also being below 1.0x in FY2024, meaning current liabilities exceeded current assets at both year-ends. Yet long-term debt was only $1.4B against $48.7B of equity, so the pressure reflects working-capital structure more than debt load.

Reinvestment is rising without consuming the cash surplus. Free cash flow margin reached 20.0% in FY2025, while capital spending reached $2.8B and free cash flow still rose to $11.8B, indicating the business funded heavier investment internally.

Financial Health Signals

Financial Health Score 43/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of AstraZeneca PLC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Not available for AstraZeneca PLC, and counted as zero in the overall score.

Growth

AstraZeneca PLC's revenue grew 8.6% year-over-year to $58.7B, a solid pace of expansion. This earns a growth score of 72/100.

Leverage

AstraZeneca PLC carries a low D/E ratio of 0.03, meaning only $0.03 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

AstraZeneca PLC's current ratio of 0.94 is below the typical benchmark, resulting in a score of 16/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

AstraZeneca PLC converts 20.0% of revenue into free cash flow ($11.8B). This strong cash generation earns a score of 85/100.

Returns

Not available for AstraZeneca PLC, and counted as zero in the overall score.

Piotroski F-Score Partial

5/7

AstraZeneca PLC passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.42x

For every $1 of reported earnings, AstraZeneca PLC generates $1.42 in operating cash flow ($14.6B OCF vs $10.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$5.7B

YoY+4.1%

QoQ-19.1%

AstraZeneca PLC held $5.7B in cash against $1.4B in long-term debt as of Q4 2025, with $30.6B of liabilities due within a year.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Shares Outstanding

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

AZN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AZN quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	$58.7B+8.6%	$54.1B+18.0%	$45.8B+3.3%	$44.4B+18.5%	$37.4B+40.6%	$26.6B+9.2%	$24.4B+10.4%	$22.1B-1.7%	$22.5B-2.3%	$23.0B-6.9%	$24.7B
Interest Expense	$1.3B-4.0%	$1.4B+22.9%	$1.1B+27.3%	$889.0M+14.9%	$774.0M+5.2%	$736.0M-48.6%	$1.4B+0.9%	$1.4B-5.9%	$1.5B+9.0%	$1.4B+28.7%	$1.1B
Income Tax	$2.2B+31.5%	$1.6B+75.9%	$938.0M+218.4%	-$792.0M-108.4%	-$380.0M-149.2%	$772.0M+140.5%	$321.0M+663.2%	-$57.0M+91.1%	-$641.0M-539.0%	$146.0M-39.9%	$243.0M
Net Income	$10.2B+45.3%	$7.0B+18.1%	$6.0B+81.0%	$3.3B+2763.5%	$115.0M-96.3%	$3.1B+156.2%	$1.2B-40.1%	$2.0B-28.5%	$2.9B-15.8%	$3.4B+20.5%	$2.8B
Diluted Shares (Avg)	1.56B-0.1%	1.56B+0.1%	1.56B+0.1%	1.56B+9.3%	1.43B+8.7%	1.31B+0.9%	1.30B+2.7%	1.27B0.0%	1.27B+0.1%	1.27B+0.1%	1.26B

Metric	Q4'2510-K	Q2'256-K	Q4'2410-K	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Revenue	N/A	$14.5B+11.7%	N/A	$12.9B+13.3%	N/A	$11.4B+6.0%	N/A	$10.8B+31.0%
Interest Expense	N/A	$439.0M-0.9%	N/A	$443.0M+2.8%	N/A	$431.0M+38.6%	N/A	$311.0M-4.6%
Income Tax	N/A	$679.0M+44.8%	N/A	$469.0M+75.0%	N/A	$268.0M+337.2%	N/A	-$113.0M-152.8%
Net Income	N/A	$2.4B+27.0%	N/A	$1.9B+5.9%	N/A	$1.8B+405.6%	N/A	$360.0M-34.5%
Diluted Shares (Avg)	N/A	1.56B-0.1%	N/A	1.56B0.0%	N/A	1.56B0.0%	N/A	1.56B+18.4%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted).

AZN Balance Sheet

AZN quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$114.1B+9.6%	$104.0B+2.9%	$101.1B+4.8%	$96.5B-8.4%	$105.4B+57.9%	$66.7B+8.7%	$61.4B+1.2%	$60.7B-4.3%	$63.4B+1.3%	$62.5B+4.1%	$60.1B
Current Assets	$28.7B+11.2%	$25.8B+3.1%	$25.1B+10.9%	$22.6B-13.9%	$26.2B+34.3%	$19.5B+25.6%	$15.6B-0.2%	$15.6B+18.6%	$13.2B-0.8%	$13.3B-17.1%	$16.0B
Cash & Equivalents	$5.7B+4.1%	$5.5B-6.0%	$5.8B-5.3%	$6.2B-2.6%	$6.3B-19.2%	$7.8B+45.9%	$5.4B+11.1%	$4.8B+45.3%	$3.3B-33.8%	$5.0B-19.6%	$6.2B
Inventory	$6.6B+24.0%	$5.3B-2.5%	$5.4B+15.4%	$4.7B-47.7%	$9.0B+123.2%	$4.0B+26.0%	$3.2B+10.5%	$2.9B-4.8%	$3.0B+30.0%	$2.3B+8.9%	$2.1B
Accounts Receivable	$15.2B+17.0%	$13.0B+7.0%	$12.1B+15.3%	$10.5B+9.1%	$9.6B+37.3%	$7.0B+21.9%	$5.8B+3.4%	$5.6B+11.3%	$5.0B+9.5%	$4.6B-30.9%	$6.6B
Goodwill	$21.2B+1.0%	$21.0B+4.9%	$20.0B+1.2%	$19.8B-0.9%	$20.0B+68.8%	$11.8B+1.5%	$11.7B-0.3%	$11.7B-1.0%	$11.8B+1.4%	$11.7B-1.2%	$11.8B
Total Liabilities	$65.4B+3.5%	$63.2B+2.0%	$62.0B+4.3%	$59.4B-10.1%	$66.1B+29.3%	$51.1B+9.2%	$46.8B+0.4%	$46.6B-0.2%	$46.7B+1.9%	$45.9B+10.4%	$41.5B
Current Liabilities	$30.6B+9.9%	$27.9B-8.8%	$30.5B+16.2%	$26.3B+16.4%	$22.6B+11.3%	$20.3B+12.1%	$18.1B+11.2%	$16.3B-0.6%	$16.4B+7.4%	$15.3B+2.6%	$14.9B
Non-Current Liabilities	$34.7B-1.6%	$35.3B+12.4%	$31.4B-5.2%	$33.1B-23.8%	$43.5B+41.2%	$30.8B+7.4%	$28.7B-5.4%	$30.3B0.0%	$30.3B-0.9%	$30.6B+14.7%	$26.7B
Long-Term Debt	$1.4B+27.7%	$1.1B+29.9%	$857.0M+18.2%	$725.0M-3.8%	$754.0M+54.2%	$489.0M+0.4%	$487.0M-97.5%	$19.1B+7.3%	$17.8B	N/A	N/A
Total Equity	$48.7B+19.2%	$40.9B+4.4%	$39.2B+5.7%	$37.1B-5.7%	$39.3B+151.2%	$15.6B+7.1%	$14.6B+3.9%	$14.0B-15.6%	$16.6B-0.2%	$16.7B-9.9%	$18.5B
Retained Earnings	$11.0B+247.2%	$3.2B+110.4%	$1.5B+361.7%	-$574.0M-133.6%	$1.7B-67.7%	$5.3B+88.4%	$2.8B-50.5%	$5.7B-30.9%	$8.2B+1.0%	$8.1B-31.2%	$11.8B

Metric	Q4'2510-K	Q2'256-K	Q4'2410-K	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Total Assets	$114.1B+9.6%	$112.4B+7.7%	$104.0B+2.9%	$104.3B+8.1%	$101.1B+4.8%	$96.5B0.0%	$96.5B-8.4%	$96.6B+31.1%
Current Assets	$28.7B+11.2%	$28.9B+14.0%	$25.8B+3.1%	$25.4B+11.2%	$25.1B+10.9%	$22.8B+9.2%	$22.6B-13.9%	$20.9B-23.3%
Cash & Equivalents	$5.7B+4.1%	$7.1B+2.1%	$5.5B-6.0%	$6.9B+22.1%	$5.8B-5.3%	$5.7B+17.6%	$6.2B-2.6%	$4.8B-69.1%
Inventory	$6.6B+24.0%	$6.5B+14.1%	$5.3B-2.5%	$5.7B+12.2%	$5.4B+15.4%	$5.1B-18.8%	$4.7B-47.7%	$6.2B+30.6%
Accounts Receivable	$15.2B+17.0%	$14.2B+28.3%	$13.0B+7.0%	$11.0B-0.4%	$12.1B+15.3%	$11.1B+24.5%	$10.5B+9.1%	$8.9B+40.2%
Goodwill	$21.2B+1.0%	$21.2B+0.8%	$21.0B+4.9%	$21.1B+5.5%	$20.0B+1.2%	$20.0B+0.7%	$19.8B-0.9%	$19.8B+68.0%
Total Liabilities	$65.4B+3.5%	$67.6B+4.4%	$63.2B+2.0%	$64.7B+9.5%	$62.0B+4.3%	$59.1B-2.5%	$59.4B-10.1%	$60.6B+4.6%
Current Liabilities	$30.6B+9.9%	$33.5B+17.4%	$27.9B-8.8%	$28.6B+8.3%	$30.5B+16.2%	$26.4B+20.9%	$26.3B+16.4%	$21.8B-1.8%
Non-Current Liabilities	$34.7B-1.6%	$34.1B-5.8%	$35.3B+12.4%	$36.2B+10.5%	$31.4B-5.2%	$32.8B-15.6%	$33.1B-23.8%	$38.8B+8.6%
Long-Term Debt	$1.4B+27.7%	$1.3B+34.0%	$1.1B+29.9%	$949.0M+31.4%	$857.0M+18.2%	$722.0M+5.4%	$725.0M-3.8%	$685.0M+39.2%
Total Equity	$48.7B+19.2%	$44.8B+13.2%	$40.9B+4.4%	$39.6B+5.8%	$39.2B+5.7%	$37.4B+4.1%	$37.1B-5.7%	$36.0B+129.1%
Retained Earnings	$11.0B+247.2%	$7.0B+280.2%	$3.2B+110.4%	$1.8B+889.3%	$1.5B+361.7%	-$234.0M+85.9%	-$574.0M-133.6%	-$1.7B-131.1%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.

AZN Cash Flow Statement

AZN quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	$14.6B+22.9%	$11.9B+14.7%	$10.3B+5.5%	$9.8B+64.5%	$6.0B+24.3%	$4.8B+61.6%	$3.0B+13.4%	$2.6B-26.8%	$3.6B-13.7%	$4.1B+24.7%	$3.3B
Depreciation & Amortization	$5.7B-14.3%	$6.7B+24.2%	$5.4B-1.7%	$5.5B-16.1%	$6.5B+107.4%	$3.1B-16.3%	$3.8B+0.2%	$3.8B+23.6%	$3.0B+28.8%	$2.4B-17.4%	$2.9B
Capital Expenditures	$2.8B+46.0%	$1.9B+41.4%	$1.4B+24.7%	$1.1B0.0%	$1.1B+13.5%	$961.0M-1.8%	$979.0M-6.1%	$1.0B-21.3%	$1.3B-8.3%	$1.4B+8.9%	$1.3B
Free Cash Flow	$11.8B+18.4%	$9.9B+10.6%	$9.0B+3.1%	$8.7B+78.9%	$4.9B+26.9%	$3.8B+92.9%	$2.0B+26.3%	$1.6B-30.1%	$2.3B-16.6%	$2.7B+35.2%	$2.0B
Investing Cash Flow	-$6.8B+14.7%	-$8.0B-96.4%	-$4.1B-37.3%	-$3.0B+73.2%	-$11.1B-3780.0%	-$285.0M+56.6%	-$657.0M-168.2%	$963.0M+141.4%	-$2.3B+41.3%	-$4.0B+6.4%	-$4.2B
Financing Cash Flow	-$7.5B-88.8%	-$4.0B+39.2%	-$6.6B+3.8%	-$6.8B-287.0%	$3.6B+265.6%	-$2.2B-24.8%	-$1.8B+13.6%	-$2.0B+30.4%	-$2.9B-121.8%	-$1.3B-250.8%	$878.0M
Dividends Paid	$5.0B+7.4%	$4.6B+3.3%	$4.5B+2.7%	$4.4B+13.2%	$3.9B+8.0%	$3.6B-0.6%	$3.6B+3.1%	$3.5B-1.0%	$3.5B-1.2%	$3.6B+2.2%	$3.5B

Metric	Q4'2510-K	Q2'256-K	Q4'2410-K	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

AZN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AZN quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Net Margin	17.4%+4.4pp	13.0%0.0pp	13.0%+5.6pp	7.4%+7.1pp	0.3%-11.5pp	11.8%+6.8pp	5.0%-4.3pp	9.3%-3.5pp	12.8%-2.0pp	14.8%+3.4pp	11.4%
Return on Equity	21.0%+3.8pp	17.2%+2.0pp	15.2%+6.3pp	8.9%+8.6pp	0.3%-19.8pp	20.1%+11.7pp	8.4%-6.2pp	14.6%-2.6pp	17.2%-3.2pp	20.4%+5.2pp	15.3%
Return on Assets	9.0%+2.2pp	6.8%+0.9pp	5.9%+2.5pp	3.4%+3.3pp	0.1%-4.6pp	4.7%+2.7pp	2.0%-1.4pp	3.4%-1.2pp	4.5%-0.9pp	5.5%+0.7pp	4.7%
Current Ratio	0.940.0x	0.93+0.1x	0.820.0x	0.86-0.3x	1.16+0.2x	0.96+0.1x	0.86-0.1x	0.96+0.2x	0.80-0.1x	0.87-0.2x	1.08
Debt-to-Equity	0.030.0x	0.030.0x	0.020.0x	0.020.0x	0.020.0x	0.030.0x	0.03-1.3x	1.36+0.3x	1.07-1.7x	2.75+0.5x	2.24
Asset Turnover	0.510.0x	0.52+0.1x	0.450.0x	0.46+0.1x	0.360.0x	0.400.0x	0.400.0x	0.360.0x	0.350.0x	0.370.0x	0.41
FCF Margin	20.0%+1.7pp	18.4%-1.2pp	19.6%0.0pp	19.7%+6.6pp	13.0%-1.4pp	14.4%+6.3pp	8.2%+1.0pp	7.1%-2.9pp	10.0%-1.7pp	11.7%+3.7pp	8.1%

Metric	Q4'2510-K	Q2'256-K	Q4'2410-K	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Net Margin	N/A	16.9%+2.0pp	N/A	14.9%-1.0pp	N/A	15.9%+12.6pp	N/A	3.3%-3.4pp
Return on Equity	N/A	5.5%+0.6pp	N/A	4.9%0.0pp	N/A	4.9%+3.9pp	N/A	1.0%-2.5pp
Return on Assets	N/A	2.2%+0.3pp	N/A	1.8%0.0pp	N/A	1.9%+1.5pp	N/A	0.4%-0.4pp
Current Ratio	0.940.0x	0.860.0x	0.93+0.1x	0.890.0x	0.820.0x	0.87-0.1x	0.86-0.3x	0.96-0.3x
Debt-to-Equity	0.030.0x	0.030.0x	0.030.0x	0.020.0x	0.020.0x	0.020.0x	0.020.0x	0.020.0x
Asset Turnover	N/A	0.130.0x	N/A	0.120.0x	N/A	0.120.0x	N/A	0.110.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, FCF Margin.

Note: The current ratio is below 1.0 (0.94), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
AstraZeneca PLC AZN	FY2025	$58.7B	$10.2B	17.4%	$244.6B	43/100
Novartis AG NVS	FY2025	N/A	$14.0B	N/A	$271.0B	—
Merck & Co., Inc. MRK	FY2025	$65.0B	$18.3B	28.1%	$358.5B	38/100
AbbVie Inc. ABBV	FY2025	$61.2B	$4.2B	6.9%	$465.3B	58/100
Johnson & Johnson JNJ	FY2025	$94.2B	$26.8B	28.5%	$638.0B	37/100

Where AstraZeneca PLC Ranks

Frequently Asked Questions

What is AstraZeneca PLC's annual revenue?

AstraZeneca PLC (AZN) reported $58.7B in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is AstraZeneca PLC's revenue growing?

AstraZeneca PLC (AZN) revenue grew by 8.6% year-over-year, from $54.1B to $58.7B in fiscal year 2025.

Is AstraZeneca PLC profitable?

Yes, AstraZeneca PLC (AZN) reported a net income of $10.2B in fiscal year 2025, with a net profit margin of 17.4%.

How much debt does AstraZeneca PLC have?

As of fiscal year 2025, AstraZeneca PLC (AZN) had $5.7B in cash and equivalents against $1.4B in long-term debt.

What is AstraZeneca PLC's net profit margin?

AstraZeneca PLC (AZN) had a net profit margin of 17.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is AstraZeneca PLC's return on equity (ROE)?

AstraZeneca PLC (AZN) has a return on equity of 21.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is AstraZeneca PLC's free cash flow?

AstraZeneca PLC (AZN) generated $11.8B in free cash flow during fiscal year 2025. This represents a 18.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is AstraZeneca PLC's operating cash flow?

AstraZeneca PLC (AZN) generated $14.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are AstraZeneca PLC's total assets?

AstraZeneca PLC (AZN) had $114.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are AstraZeneca PLC's capital expenditures?

AstraZeneca PLC (AZN) invested $2.8B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

What is AstraZeneca PLC's current ratio?

AstraZeneca PLC (AZN) had a current ratio of 0.94 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is AstraZeneca PLC's debt-to-equity ratio?

AstraZeneca PLC (AZN) had a debt-to-equity ratio of 0.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is AstraZeneca PLC's return on assets (ROA)?

AstraZeneca PLC (AZN) had a return on assets of 9.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is AstraZeneca PLC's P/E ratio?

AstraZeneca PLC (AZN) trades at 23.9x earnings, its market capitalization divided by net income of $10.2B net income, FY2025. The market capitalization is $244.6B as of Oct 1, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is AstraZeneca PLC's price-to-sales ratio?

AstraZeneca PLC (AZN) trades at 4.2x sales, its market capitalization divided by revenue of $58.7B revenue, FY2025. The market capitalization is $244.6B as of Oct 1, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is AstraZeneca PLC's Piotroski F-Score?

AstraZeneca PLC (AZN) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AstraZeneca PLC's earnings high quality?

AstraZeneca PLC (AZN) has an earnings quality ratio of 1.42x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is AstraZeneca PLC?

AstraZeneca PLC (AZN) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.